GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Applied Therapeutics
Applied Therapeutics is a biotech company developing drugs to treat rare diseases. Its stock price is volatile and depends on clinical trial results and FDA decisions. The chart is a story of the hopes associated with its scientific platform.
Share prices of companies in the market segment - Specialized pharma
Applied Therapeutics is a clinical-stage biopharmaceutical company developing aldose reductase inhibitors for the treatment of rare metabolic and cardiac diseases. We have classified it in the "Specialized Pharma" segment. The chart below shows the overall performance of the sector, which focuses on rare diseases.
Broad Market Index - GURU.Markets
Applied Therapeutics is a biopharmaceutical company developing drugs to treat rare metabolic diseases. It is a component of the GURU.Markets index. The chart below represents the market. See how clinical trial successes impact this company's stock price.
Change in the price of a company, segment, and market as a whole per day
APLT - Daily change in the company's share price Applied Therapeutics
For Applied Therapeutics, which develops drugs for rare diseases, daily price changes are a measure of enormous volatility. This metric reflects extreme sensitivity to clinical trial data and FDA decisions, and is key to assessing risk.
Daily change in the price of a set of shares in a market segment - Specialized pharma
Applied Therapeutics, Inc. is a biotech company. This chart shows the sector's extreme volatility. Comparison with APLT, which focuses on rare disease treatments, helps assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Applied Therapeutics is a biotech company specializing in the treatment of rare metabolic diseases. Its shares move in sync with clinical trial news, and their high volatility is part of the overall market movement where science meets finance.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Applied Therapeutics
Applied Therapeutics' year-over-year performance is a story of drug development for rare metabolic and cardiac diseases. Its 12-month market cap is critically dependent on FDA decisions. Successful approval of its lead candidate could be a breakthrough, but regulatory delays are a serious blow to its valuation.
Annual dynamics of market capitalization of the market segment - Specialized pharma
Applied Therapeutics, Inc. is a late-stage biotech company developing drugs for rare diseases. Its stock price is entirely dependent on clinical trial results and regulatory decisions. The chart reflects high risks and breakthrough potential.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Applied Therapeutics is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Applied Therapeutics
Applied Therapeutics is a late-stage biotech company developing drugs for rare diseases. Its monthly performance is extremely sensitive to regulatory decisions. FDA news regarding its drugs can cause significant price movements.
Monthly dynamics of market capitalization of the market segment - Specialized pharma
Drug development for rare metabolic diseases is a niche in biotech where unmet patient needs create significant opportunities. The dynamics of this sector, shown in the graph, reflect its dependence on clinical data. Applied Therapeutics operates in this environment.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Applied Therapeutics develops drugs to treat rare diseases. Like many biotech companies, its shares are driven by news of clinical trials and regulatory decisions. Their performance is completely disconnected from the broader market.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Applied Therapeutics
Shares of Applied Therapeutics, a biopharmaceutical company focused on treating rare diseases, have been experiencing high volatility on a weekly basis. News about the progress of its drugs' FDA review, as well as clinical trial data, have caused sharp price surges.
Weekly dynamics of market capitalization of the market segment - Specialized pharma
Applied Therapeutics and the entire rare disease biotech sector are moving in tandem with investor sentiment and regulatory news. These factors are creating general volatility for everyone. The chart will show how the company fares in this risky but promising field.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Applied Therapeutics and the entire rare disease biotech sector are moving in tandem with investor sentiment and regulatory news. These factors are creating general volatility for everyone. The chart will show how the company fares in this risky but promising field.
Market capitalization of the company, segment and market as a whole
APLT - Market capitalization of the company Applied Therapeutics
Applied Therapeutics' market capitalization is the financial valuation of a biotech company developing drugs to treat rare metabolic diseases. The chart reflects both the scientific potential of its developments and the delays and uncertainty of the regulatory approval process. Its volatile dynamics tell the story of how investor expectations collide with FDA reality.
APLT - Share of the company's market capitalization Applied Therapeutics within the market segment - Specialized pharma
Applied Therapeutics develops small-molecule drugs for the treatment of rare metabolic and cardiovascular diseases. Its sector share reflects the potential of its leading developments. The chart below shows how its share changes based on regulatory announcements and clinical trial results.
Market capitalization of the market segment - Specialized pharma
Applied Therapeutics develops drugs to treat rare metabolic diseases. The chart below shows the overall market capitalization of this entire sector. Its dynamics reflect both scientific breakthroughs and the high-risk nature of clinical trials. Applied Therapeutics is betting on several promising molecules.
Market capitalization of all companies included in a broad market index - GURU.Markets
The biotechnologies visible in the chart treat complications of diabetes. Applied Therapeutics develops drugs to treat conditions caused by excess sugar in the body. Its capitalization is a risky bet that its drugs will prevent serious complications in diabetics.
Book value capitalization of the company, segment and market as a whole
APLT - Book value capitalization of the company Applied Therapeutics
Applied Therapeutics' book value is capital used to combat rare metabolic diseases. Currently in the R&D stage, the company is using its financial assets to conduct clinical trials of drugs targeting aldose reductase inhibition, which could help treat diabetic complications.
APLT - Share of the company's book capitalization Applied Therapeutics within the market segment - Specialized pharma
Applied Therapeutics, a clinical-stage biopharmaceutical company, focuses on developing drugs for rare diseases. Its share of the sector's assets consists of R&D laboratories. At this stage, its value lies in the potential of its investigational drugs.
Market segment balance sheet capitalization - Specialized pharma
Applied Therapeutics is a clinical-stage biotech company, which accounts for its low capital intensity. Its value lies in developing drugs for rare diseases. Compared to the pharmaceutical sector as a whole, its "light" balance sheet is typical of companies focused on R&D.
Book value of all companies included in the broad market index - GURU.Markets
Applied Therapeutics' assets represent scientific capital focused on the development of aldose reductase inhibitors for the treatment of rare metabolic diseases. The company's balance sheet reflects the value of its clinical programs. The chart shows the amount of resources invested in targeted therapy for patients with previously untreatable conditions.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Applied Therapeutics
Applied Therapeutics develops drugs to treat rare diseases. Its market capitalization reflects investors' hopes for the approval and commercial success of its candidates. This is a classic biotech story, where future potential is valued far more than current assets.
Market to book capitalization ratio in a market segment - Specialized pharma
Applied Therapeutics develops drugs to treat rare diseases. Its value depends almost entirely on the results of clinical trials. This chart illustrates a classic biotech scenario, where market valuation reflects potential peak drug sales rather than tangible assets.
Market to book capitalization ratio for the market as a whole
Applied Therapeutics is a biopharmaceutical company developing drugs for rare diseases. Its market capitalization reflects investor expectations for the success of clinical trials. This chart shows the significant premium the market places on scientific potential, even when the company has virtually no tangible assets.
Debts of the company, segment and market as a whole
APLT - Company debts Applied Therapeutics
Applied Therapeutics develops drugs to treat rare diseases. For companies targeting niche markets, the path to approval requires significant investment in clinical trials. This chart shows how the company uses funding to advance its developments through regulatory hurdles.
Market segment debts - Specialized pharma
Applied Therapeutics is a clinical-stage biopharmaceutical company focused on developing drugs for rare diseases. Funding in this field is almost always through equity. This chart shows whether the company adheres to this standard model for funding its expensive and risky research.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Applied Therapeutics
Applied Therapeutics develops drugs for rare diseases. This chart shows its level of debt. Funding research with debt is risky, as drug development takes time and requires significant resources. If the drug fails to receive regulatory approval, the company will face serious financial problems.
Market segment debt to market segment book capitalization - Specialized pharma
Applied Therapeutics develops drugs to treat rare metabolic diseases for which there are few effective treatments. This chart compares the debt raised to fund clinical trials to the overall market capitalization of the specialty pharmaceutical sector. It illustrates the financial side of the fight for the health of patients with rare diagnoses.
Debt to book value of all companies in the market
Applied Therapeutics develops drugs to treat rare diseases, which requires significant and risky investments in R&D. The chart illustrates the company's financial strategy: whether it relies on equity or debt. A comparison with the overall level of debt in the pharmaceutical industry helps assess its sustainability and dependence on external financing.
P/E of the company, segment and market as a whole
P/E - Applied Therapeutics
For Applied Therapeutics, a company developing drugs for rare diseases, this chart is an assessment of its scientific potential. The stock price relative to future earnings reflects investor expectations regarding the approval of its drug candidates. The dynamics are a direct response to regulatory decisions and clinical trial data.
P/E of the market segment - Specialized pharma
This chart reflects the average valuation for the speculative biotech sector—a benchmark for Applied Therapeutics. For investors, it serves as a benchmark, reflecting the overall level of optimism in the field of rare disease treatments. This provides a useful context for assessing expectations for the company's developments and its chances of receiving regulatory approval.
P/E of the market as a whole
Applied Therapeutics develops drugs to treat rare metabolic diseases. It's a classic story of a biotech company whose fate hinges on clinical trial results and regulatory decisions. This chart shows the overall interest in biotech. It helps understand how the market views the company's scientific prospects and its chances of bringing drugs to market for niche but highly targeted patient groups.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Applied Therapeutics
Applied Therapeutics develops aldose reductase inhibitors for the treatment of rare metabolic diseases. For a company in late-stage clinical development, this chart is an indicator of regulatory expectations. It shows whether analysts believe the drugs will be approved and will be able to find their niche in the market.
%20P%2FE%20Applied%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Applied-Therapeutics&v=1772629812986 "Chart of the company's future (projected) P/E Applied Therapeutics")
Future (projected) P/E of the market segment - Specialized pharma
Applied Therapeutics develops small-molecule drugs targeting the enzyme aldose reductase to treat rare metabolic diseases. This chart compares its future profitability expectations with those of the biotech sector. It helps understand how the market views the scientific soundness of its approach and the potential of its drugs in clinical trials.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Specialized-pharma&v=1772629813098 "Future (projected) P/E graph of the market segment - Specialized pharma")
Future (projected) P/E of the market as a whole
Applied Therapeutics is a clinical-stage biopharmaceutical company targeting diseases with high unmet needs. This chart reflects overall risk appetite. For APLT, clinical trial results are fundamental. A positive market environment helps with funding, but cannot overcome poor scientific data.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772629813195 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Applied Therapeutics
Applied Therapeutics is a clinical-stage biopharmaceutical company developing new drugs to treat severe, rare diseases. This chart illustrates the financial impact of scientific discoveries. Current results reflect investments in clinical trials aimed at developing therapies for patients with unmet medical needs.
Profit of companies in the market segment - Specialized pharma
Applied Therapeutics is a clinical-stage biopharmaceutical company developing drugs to treat rare metabolic diseases with high unmet needs. This chart illustrates the overall profitability of the niche pharmaceutical sector, demonstrating how much the market is willing to reward companies for developing drugs for orphan diseases.
Overall market profit
Applied Therapeutics develops drugs to treat rare diseases. Demand for its products will be determined by medical needs and drug efficacy, not by the economy. This makes the company's business potentially non-cyclical. However, before entering the market, it relies on funding, which is easier to raise in a favorable economic environment.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Applied Therapeutics
Applied Therapeutics develops drugs to treat rare metabolic and cardiac diseases. The company is in late-stage clinical development. This chart reflects analyst expectations regarding the likelihood of approval of its key drugs and their potential commercial success.
%20profit%20of%20the%20company%20Applied%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Applied-Therapeutics&v=1772629813398 "Graph of future (projected) profit of the company Applied Therapeutics")
Future (predicted) profit of companies in the market segment - Specialized pharma
Applied Therapeutics focuses on developing new drugs to treat severe, rare diseases with high unmet needs. This chart shows forecasts for the biotech sector. The company's future profitability depends on the clinical success of its targeted therapies and regulatory approval for their market entry, where they can enjoy exclusive status.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Specialized-pharma&v=1772629813459 "Graph of future (predicted) profits of companies in a market segment - Specialized pharma")
Future (predicted) profit of the market as a whole
Applied Therapeutics develops drugs for rare and serious diseases. The introduction of new, often expensive, drugs into clinical practice depends on the financial health of the healthcare system. This graph, reflecting corporate profit forecasts, indirectly indicates future opportunities for funding innovative medicine and purchasing advanced drugs.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772629813510 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Applied Therapeutics
Applied Therapeutics develops drugs to treat rare metabolic diseases. While in clinical development, the company has minimal revenue. This chart demonstrates that its market value is almost entirely determined by investors' faith in the success of clinical trials and the future commercial potential of its drugs.
P/S market segment - Specialized pharma
Applied Therapeutics develops new drugs to treat severe, rare diseases with high unmet needs. The company focuses on aldose reductase inhibitors. This chart reflects the average biotech valuation, helping to understand how highly investors view the potential of Applied Therapeutics' developments in their niche yet important areas.
P/S of the market as a whole
Applied Therapeutics develops drugs to treat rare metabolic diseases for which there is currently no effective therapy. It's a high-risk, but potentially highly profitable, business. This revenue valuation indicator emphasizes that investors are evaluating not current sales, but the hope of developing a breakthrough drug.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Applied Therapeutics
Applied Therapeutics develops drugs to treat rare metabolic diseases. This chart reflects investor expectations for the future success of its clinical programs. This valuation is based on the potential revenue from its drug candidates if approved, as they target markets with unmet medical needs.
%20P%2FS%20Applied%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Applied-Therapeutics&v=1772629814036 "The graph of the company's future (projected) P/S Applied Therapeutics")
Future (projected) P/S of the market segment - Specialized pharma
Applied Therapeutics develops drugs to treat rare metabolic and cardiac diseases. This chart compares the company's future revenue expectations with its industry. It reflects investor confidence in the scientific soundness of its developments and the commercial potential of its drug candidates.
%20P%2FS%20market%20segment%20graph%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Specialized-pharma&v=1772629814091 "Future (projected) P/S market segment graph - Specialized pharma")
Future (projected) P/S of the market as a whole
Applied Therapeutics develops small-molecule drugs to treat rare metabolic diseases. This chart shows overall revenue expectations, and Applied Therapeutics is an example of a source of these. Success in its drugs for galactosemia and other rare diseases could dramatically change patients' lives and create a new market.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772629814159 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Applied Therapeutics
Applied Therapeutics is a clinical-stage biopharmaceutical company developing drugs for rare diseases. Its revenue, shown in this chart, is generated not from drug sales but from payments under collaboration agreements that help fund its clinical trials.
Sales of companies in the market segment - Specialized pharma
Applied Therapeutics is a biopharmaceutical company developing drugs to treat rare metabolic diseases with high unmet needs. Their research focuses on specific enzymes. This graph reflects the dynamics of the pharmaceutical industry, where focusing on orphan diseases can lead to the development of life-saving drugs.
Overall market sales
Applied Therapeutics is a clinical-stage biopharmaceutical company focused on treating rare diseases. Its operations require significant, long-term investment. The growth in overall economic activity, reflected in this chart, is creating a more favorable environment for raising capital. Investors are more willing to fund promising, but risky, scientific developments.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Applied Therapeutics
Applied Therapeutics develops small-molecule drugs targeting rare diseases with high unmet needs. This chart reflects analyst expectations for the clinical trial results of its candidates and the potential market launch of these niche, yet vital, drugs.
%20sales%20of%20the%20company%20Applied%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Applied-Therapeutics&v=1772629814716 "Schedule of future (projected) sales of the company Applied Therapeutics")
Future (projected) sales of companies in the market segment - Specialized pharma
Applied Therapeutics develops small-molecule drugs targeting aldose reductase for the treatment of rare and severe diseases. This chart shows the outlook for specialty pharmaceuticals. It helps understand how the company is pursuing its niche by solving complex medical problems with targeted therapies.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Specialized-pharma&v=1772629814764 "Schedule of future (projected) sales of companies in the market segment - Specialized pharma")
Future (projected) sales of the market as a whole
Applied Therapeutics, which focuses on treating rare diseases, sees this chart as a marker of the stability of the healthcare system. The positive economic forecasts reflected here ensure predictable funding for programs covering the costs of expensive orphan drugs, which is critical to the company's commercial success.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772629814932 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Applied Therapeutics
Applied Therapeutics is a clinical-stage biopharmaceutical company focused on developing drugs for rare diseases. This chart illustrates the financial side of its research. It doesn't show current profits, but rather the amount of capital the company invests in clinical trials to develop new treatments.
Market segment marginality - Specialized pharma
Applied Therapeutics develops drugs to treat rare diseases with high unmet needs. Focusing on niche markets can provide a cost advantage, but requires effective research. The chart shows how profitable the company's business model, targeting rare diseases, is compared to that of pharmaceutical giants.
Market marginality as a whole
Applied Therapeutics develops drugs to treat rare metabolic diseases. This graph shows average profitability, and Applied Therapeutics focuses on niches with high unmet needs. Their financial success depends on the approval of their drugs, which can receive orphan designation and a premium price.
Employees in the company, segment and market as a whole
Number of employees in the company Applied Therapeutics
Applied Therapeutics is a clinical-stage biotech company focused on treating rare diseases. This chart shows the size of its focused team. Staff growth, especially as it moves into late-stage trials, is an important signal that a new drug is getting closer to potential market launch.
Share of the company's employees Applied Therapeutics within the market segment - Specialized pharma
Applied Therapeutics develops new drugs to treat severe metabolic diseases. Its success depends on its team of scientists and clinicians. This chart shows the percentage of all specialists the company concentrates in its narrow therapeutic area, which is a direct indicator of its scientific potential and focus on breakthrough research.
Number of employees in the market segment - Specialized pharma
Applied Therapeutics is a clinical-stage biopharmaceutical company focused on treating rare metabolic diseases. Its core asset is its scientific team. This chart shows how the company is investing in its research. Headcount growth is an indicator of progress in clinical trials and approaching potential approval.
Number of employees in the market as a whole
Applied Therapeutics develops drugs for rare diseases. For such companies, the overall economic situation, as reflected in the chart, is less important than regulatory decisions (like those from the FDA). Approval of a new drug opens market access and requires a significant increase in staffing for its commercialization.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Applied Therapeutics (APLT)
Applied Therapeutics is an R&D company focused on rare diseases. Its market capitalization reflects investors' hopes for the approval and commercialization of its drugs. The very high value on this chart is typical for biotech, where a small team of scientists can create a product worth billions of dollars.
%20of%20the%20company%20Applied%20Therapeutics%20(APLT)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Applied-Therapeutics-APLT&v=1772629815593 "Chart of market capitalization per employee (in thousands of dollars) of the company Applied Therapeutics (APLT)")
Market capitalization per employee (in thousands of dollars) in the market segment - Specialized pharma
Applied Therapeutics develops drugs to treat rare diseases with high unmet demand. The valuation of these companies is based on the uniqueness of their approach and potential market size. This metric demonstrates how highly investors value the company's scientific developments, given its small and focused team.
%20by%20market%20segment%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Specialized-pharma&v=1772629815621 "Market capitalization per employee (in thousands of dollars) by market segment - Specialized pharma")
Market capitalization per employee (in thousands of dollars) for the overall market
Applied Therapeutics is a clinical-stage biopharmaceutical company developing drugs to treat rare metabolic diseases. Its value depends on its research success. The chart demonstrates the high market valuation of a small scientific team whose work could lead to the creation of life-saving drugs for niche patient groups.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772629815639 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Applied Therapeutics (APLT)
Applied Therapeutics is a biopharmaceutical company developing drugs for the treatment of rare metabolic diseases. It's an R&D company. This chart shows the capital burn on research per scientist. This represents an investment in scientific development that could generate significant profits in the future if the drugs are approved.
%20Chart%20Applied%20Therapeutics%20(APLT)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Applied-Therapeutics-APLT&v=1772629815736 "Company Profit Per Employee (in thousands of dollars) Chart Applied Therapeutics (APLT)")
Profit per employee (in thousands of dollars) in the market segment - Specialized pharma
Applied Therapeutics (APLT) is a clinical-stage biopharmaceutical company developing drugs for the treatment of rare (orphan) diseases. They focus on aldose reductase inhibitors. This graph demonstrates the effectiveness of their R&D model, demonstrating how successfully their small team of scientists and management advances their highly specialized research.
%20in%20the%20market%20segment%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Specialized-pharma&v=1772629815830 "Chart of profit per employee (in thousands of dollars) in the market segment - Specialized pharma")
Profit per employee (in thousands of dollars) for the market as a whole
Applied Therapeutics is a clinical-stage biotech company specializing in rare diseases. Like most R&D companies in this field, its business is science. This graph would show negative profit per employee, as its staff of scientists and doctors generates data for the FDA, not revenue. This represents a direct investment in intellectual property.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772629815904 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Applied Therapeutics (APLT)
Applied Therapeutics is a biopharmaceutical company specializing in the treatment of rare diseases. At the clinical trial stage, this graph reflects future potential. Significant revenue per employee will only emerge after the drug is approved, at which point it will demonstrate how a small team can bring a breakthrough drug to market.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Applied-Therapeutics-APLT&v=1772629815962 "Sales chart per company employee Applied Therapeutics (APLT)")
Sales per employee in the market segment - Specialized pharma
Applied Therapeutics develops drugs to treat rare metabolic diseases, a complex niche in the pharmaceutical industry. This chart shows the average revenue per employee in the sector. It helps assess the level of productivity required in this industry to monetize drugs for orphan diseases and serves as a benchmark for the company.
Sales per employee for the market as a whole
Applied Therapeutics (APLT) is a clinical-stage biopharmaceutical company developing drugs for the treatment of rare metabolic diseases. It is a knowledge-intensive R&D company. Revenue during the research phase is minimal. This chart shows the current (zero) commercial return per scientist pending drug approval.
Short shares by company, segment and market as a whole
Shares shorted by company Applied Therapeutics (APLT)
Applied Therapeutics is a biopharmaceutical company specializing in rare metabolic diseases. Its key drug has faced FDA approval delays. This chart shows the number of investors betting that the drug will not be approved or that its market potential will be very small, which would devalue the entire company.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Applied-Therapeutics-APLT&v=1772629816128 "Short Shares Chart for the Company Applied Therapeutics (APLT)")
Shares shorted by market segment - Specialized pharma
Applied Therapeutics develops drugs for rare metabolic and cardiac diseases. This chart reflects the bearish sentiment in the sector. It shows how skeptical investors are overall about the commercial potential of orphan disease drugs, anticipating challenges with approval or pricing.
Shares shorted by the overall market
Applied Therapeutics develops drugs for rare metabolic diseases. This chart illustrates the overall market pessimism. For biotech companies dependent on FDA decisions, rising fears mean that any delay or negative signal from the regulator will be perceived by the market as a catastrophe, leaving no room for error.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Applied Therapeutics (APLT)
This chart for Applied Therapeutics is a barometer of regulatory risk. The company targets rare diseases, which often utilize the FDA's accelerated approval process. Investors are overhyping the stock (above 70) in anticipation of the regulatory approval date. However, receiving a "complete response" (CRL) from the FDA, which requires new data rather than approval, immediately sends the oscillator into oversold territory (below 30).
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Applied-Therapeutics-APLT&v=1772629816297 "RSI 14 indicator chart for the company's stock Applied Therapeutics (APLT)")
RSI 14 Market Segment - Specialized pharma
Applied Therapeutics (APLT) is a biotech company focused on aldose reductase. They are developing inhibitors of this enzyme to treat rare metabolic (galactosemia) and cardiac diseases. The Specialized Pharma (biotech) sector thrives on news. RSI_14_Seg shows the "temperature" of this entire segment. It's vital to understand: is APLT's growth due to their R&D, or is the entire biotech sector "overheated"?
RSI 14 for the overall market
Applied Therapeutics (APLT) is a biotech R&D company. Like everyone in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic poses the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast APLT (Applied Therapeutics)
Applied Therapeutics (APLT) is a biopharmaceutical company developing drugs to treat rare metabolic and cardiac diseases. This chart shows the average 12-month forecast, reflecting analysts' confidence in the FDA approval and commercial potential of its lead candidates.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-APLT-Applied-Therapeutics&v=1772629816451 "A chart showing analyst consensus forecasts for the expected stock price. APLT (Applied Therapeutics)")
The difference between the consensus estimate and the actual stock price APLT (Applied Therapeutics)
Applied Therapeutics (APLT) is a biotech company developing drugs (aldose reductase inhibitors) for the treatment of rare metabolic diseases (galactosemia). This chart is a barometer of their R&D. It measures the gap between the price and the consensus target, reflecting the high potential analysts see in their pipeline.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-APLT-Applied-Therapeutics&v=1772629816500 "A chart showing the difference between the consensus forecast and the actual stock price. APLT (Applied Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Specialized pharma
Applied Therapeutics is a biotech company developing small-molecule drugs (aldose reductase inhibitors) for the treatment of rare metabolic diseases. This chart shows the overall expectations for the specialty pharmaceutical sector. It reflects whether experts believe this R&D approach will be successful.
Analysts' consensus forecast for the overall market share price
Applied Therapeutics is a clinical-stage biotech company specializing in metabolic diseases. It's an R&D company that's burning cash. This chart, reflecting the market's overall risk appetite, is vital. When optimism is high, investors fund speculative research. When pessimism ("risk-off") takes over, funding for biotechs like APLT disappears.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Applied Therapeutics
Applied Therapeutics is a clinical-stage biotech company. They develop targeted drugs (aldose reductase inhibitors) for the treatment of rare metabolic and neurological diseases, often orphan diseases. This chart is a clear indicator of faith in their science. Its dynamics reflect the market's speculative assessment of their R&D platform, clinical trial data, and their chances of FDA approval.
AKIMA Market Segment Index - Specialized pharma
Applied Therapeutics (APLT) is a biopharmaceutical company developing aldose reductase inhibitors for the treatment of rare metabolic and cardiovascular diseases. The chart shows the segment's average index, helping investors assess how this highly specialized scientific strategy compares to the average level of risk and expectations in the pharmaceutical industry.
The AKIM Index for the overall market
Applied Therapeutics is a biopharmaceutical company developing aldose reductase inhibitors for the treatment of rare diseases (galactosemia). This chart, which reflects the market average, provides a macro backdrop. It helps assess how this company, which is awaiting regulatory decisions, compares to overall economic trends.
